A 32-year-old male developed neuropsychiatric symptoms 2 weeks after starting mefloquine 250 mg/week for malaria prophylaxis. He continued to take the medication for the next 4 months. Initial symptoms included vivid dreams and anxiety, as well as balance problems. These symptoms persisted and progressed over the next 4 years to include vertigo, emotional lability, and poor short-term memory, which have greatly affected his personal and professional life. An extensive evaluation revealed objective evidence supporting a central vestibulopathy. These symptoms have been unresponsive to pharmacologic therapy and psychotherapy. A Naranjo assessment score of 6 was obtained for his initial symptoms, indicating a probable adverse drug reaction to mefloquine given the relationship between the clinical picture and drug exposure.
- MEFLOQUINE MASS TORT LAWSUIT UNDERWAY IN CANADA
- DAVE BONA – PTSD AND MEFLOQUINE
- The Quinism Foundation Calls on Veterans Affairs Canada to Screen Recent Canadian Veterans for Symptomatic Mefloquine Exposure
- Service members believe suicides are linked to use of anti-malaria drug
- Veterans allege devastating side effects from anti-malaria drug they were ordered to take